Premium
Sequencing of novel agents in relapsed/refractory B‐cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia
Author(s) -
Badar Talha,
Szabo Aniko,
Dinner Shira,
Liedtke Michaela,
Burkart Madelyn,
Shallis Rory M.,
Yurkiewicz Ilana R.,
Kuo Eric,
Khan Muhammad Ali,
Balasubramanian Suresh,
Yang Jay,
Hefazi Mehrdad,
Podoltsev Nikolai,
Patel Anand,
Curran Emily,
Wang Amy,
Arslan Shukaib,
Aldoss Ibrahim,
Siebenaller Caitlin,
Mattison Ryan J.,
Litzow Mark R.,
Wadleigh Martha,
Advani Anjali S.,
Atallah Ehab
Publication year - 2021
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/cncr.33340
Subject(s) - blinatumomab , medicine , refractory (planetary science) , discontinuation , hematopoietic stem cell transplantation , salvage therapy , adverse effect , lymphoblastic leukemia , gastroenterology , oncology , transplantation , leukemia , chemotherapy , physics , astrobiology
Background The availability of novel agents (NAs), including blinatumomab and inotuzumab ozogamicin (InO), has improved the outcomes of patients with relapsed/refractory (RR) B‐cell acute lymphoblastic leukemia (ALL). Because of the relative effectiveness, it is often a challenge for clinicians to determine how to best sequence these NAs with respect to efficacy and toxicity. Methods In this multicenter, retrospective study of patients with RR ALL treated with blinatumomab, InO, or both, their efficacy as a first or second NA was compared. Results Among 276 patients, 221 and 55 received blinatumomab and InO, respectively, as a first NA therapy. The complete remission (CR)/complete remission with incomplete count recovery (CRi) rate was 65% and 67% for the blinatumomab and InO groups, respectively ( P = .73). The rate of treatment discontinuation due to adverse events was 4% and 7% in the blinatumomab and InO groups, respectively. Ninety‐two patients (43%) in the blinatumomab group and 13 patients (29%) in the InO group proceeded with allogeneic hematopoietic stem cell transplantation. The median overall survival (OS) was 15 and 11.6 months in the blinatumomab and InO groups, respectively. A subset analysis was performed for 61 patients who received both NAs (blinatumomab and then InO [n = 40] or InO and then blinatumomab [n = 21]). The CR/CRi rate was 58% for patients who received InO as the second NA and 52% for patients who received blinatumomab as the second NA. The median OS was 10.5 for patients who received InO as the second NA and 5.9 months for patients who received blinatumomab as the second NA ( P = .09). Conclusions Although the limited power of this study to detect a significant difference between subgroups is acknowledged, the data suggest that blinatumomab and InO may have comparable efficacy as a first or second NA therapy in RR ALL.